-
Awan A R, Zahoor M Y, Javed M M, Babar M E, Saleem Z. 2012. Expression of pres2/S antigen of hepatitis B virus isolated from Pakistan in yeast cells. Pak. J. Bot., 44: 355-359.
-
Cabral G A, Marciano-Cabral F, Funk G A, Sanchez Y, Hollinger F B, Melnick J L, Dreesman G R. 1978. Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen. J Gen Virol, 38: 339-350.
doi: 10.1099/0022-1317-38-2-339
-
Chen H, Chuai X, Deng Y, Wen B, Wang W, Xiong S, Ruan L, Tan W. 2012. Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine. PLoS One, 7: e43730.
doi: 10.1371/journal.pone.0043730
-
Chi S W, Kim D H, Kim J S, Lee M K, Han K H. 2006. Solution conformation of an immunodominant epitope in the hepatitis B virus preS2 surface antigen. Antiviral Res, 72: 207-215.
doi: 10.1016/j.antiviral.2006.06.009
-
Faber K N, Haima P, Harder W, Veenhuis M, Ab G. 1994. Highly-effi cient electrotransformation of the yeast Hansenula polymorpha. Curr Genet, 25: 305-310.
doi: 10.1007/BF00351482
-
G. Birkenmeyer L. 2003. Hepatitis B virus: life cycle and morphogenesis. In: Ias K M (ed.), Perspectives in Medical Virology, vol. Volume 10. Elsevier, p109-125.
doi: 10.1016/S0168-7069(03)10004-3
-
Gellissen G, Janowicz Z A, Weydemann U, Melber K, Strasser A W, Hollenberg C P. 1992. High-level expression of foreign genes in Hansenula polymorpha. Biotechnol Adv, 10: 179-189.
doi: 10.1016/0734-9750(92)90002-Q
-
Hadiji-Abbes N, Borchani-Chabchoub I, Triki H, Ellouz R, Gargouri A, Mokdad-Gargouri R. 2009. Expression of HBsAg and preS2-S protein in different yeast based system: a comparative analysis. Protein Expr Purif, 66: 131-137.
doi: 10.1016/j.pep.2009.03.006
-
Hardy E, Martinez E, Diago D, Diaz R, Gonzalez D, Herrera L. 2000. Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. J Biotechnol, 77: 157-167.
doi: 10.1016/S0168-1656(99)00201-1
-
Huang Y, Bi J, Zhang Y, Zhou W, Li Y, Zhao L, Su Z. 2007. A highly effi cient integrated chromatographic procedure for the purifi cation of recombinant hepatitis B surface antigen from Hansenula polymorpha. Protein Expr Purif, 56: 301-310.
doi: 10.1016/j.pep.2007.08.009
-
Janssen H L, van Zonneveld M, Senturk H, Zeuzem S, Akarca U S, Cakaloglu Y, Simon C, So T M, Gerken G, de Man R A, Niesters H G, Zondervan P, Hansen B, Schalm S W. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, 365: 123-129.
doi: 10.1016/S0140-6736(05)17701-0
-
Kuroda S, Fujisawa Y, Iino S, Akahane Y, Suzuki H. 1991. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine, 9: 163-169.
doi: 10.1016/0264-410X(91)90148-Y
-
Langley K E, Egan K M, Barendt J M, Parker C G, Bitter G A. 1988. Characterization of purified hepatitis B surface antigen containing pre-S(2) epitopes expressed in Saccharomyces cerevisiae. Gene, 67: 229-245.
doi: 10.1016/0378-1119(88)90400-3
-
Lian M, Zhou X, Chen B, Li C, Gu X, Luo M, Zheng X. 2008. Identifi cation of the critical regions in hepatitis B virus preS required for its stability. J Pept Sci, 14: 307-312.
doi: 10.1002/psc.929
-
Liaw Y F, Leung N W, Chang T T, Guan R, Tai D I, Ng K Y, Chien R N, Dent J, Roman L, Edmundson S, Lai C L. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 119: 172-180.
doi: 10.1053/gast.2000.8559
-
Milich D R, Thornton G B, Neurath A R, Kent S B, Michel M L, Tiollais P, Chisari F V. 1985. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science, 228: 1195-1199.
doi: 10.1126/science.2408336
-
Niederau C, Heintges T, Lange S, Goldmann G, Niederau C M, Mohr L, Haussinger D. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med, 334: 1422-1427.
doi: 10.1056/NEJM199605303342202
-
Sjogren M H. 2005. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med, 118 Suppl 10A: 34S-39S.
-
Torbenson M, Thomas D L. 2002. Occult hepatitis B. Lancet Infect Dis, 2: 479-486.
doi: 10.1016/S1473-3099(02)00345-6
-
Jiang Z G, Wang Y, Shao X A, Yue Y, Hong X W, Xu L, Xiong S D. 2007. Antibodized gene vaccine harboring to HBV PreS2/S gene can enhance HBV specifi c CTL response induced by gene immunization. Chinese J Immunol, 963-967. (In Chinese)